



BIODIEM LTD
ABN 20 096 845 993
Level 4,
100 Albert Rd,
South Melbourne, Victoria, 3205
Australia
Phone: +613 9692 7240
Web: www.biodiem.com

Announcement

Wholesale Investor's Sydney Capital Showcase and Australia Biotech Invest, Melbourne

Melbourne, 5 December 2014:

BioDiem's CEO, Julie Phillips presented at the Wholesale Investor Sydney Capital Showcase held on Thursday 20 November 2014 in Sydney and the Australia Biotech Invest event held in Melbourne on 3rd and 4th December.

The BioDiem presentation focused on BioDiem's BDM-I and the opportunity presented by the antimicrobial for collaboration and investment.

ENDS

About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company developing vaccines and antimicrobials targeting treatment and prevention of infectious diseases and related cancers. BioDiem's business model is to generate income from partnerships including with other vaccine development companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine used for seasonal and pandemic influenza vaccines and is given intranasally. For additional information, please visit www.biodiem.com

Further information

Julie Phillips, Chief Executive Officer
BioDiem Ltd
Phone +61 3 9692 7240
Email jphillips@biodiem.com
Twitter @biodiem